Equities research analysts expect Solid Biosciences Inc. (NASDAQ:SLDB – Get Rating) to announce sales of $3.48 million for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Solid Biosciences’ earnings. The lowest sales estimate is $3.00 million and the highest is $3.90 million. Solid Biosciences reported sales of $3.59 million in the same quarter last year, which would suggest a negative year over year growth rate of 3.1%. The company is expected to announce its next quarterly earnings report on Monday, January 1st.
On average, analysts expect that Solid Biosciences will report full-year sales of $9.99 million for the current fiscal year, with estimates ranging from $5.50 million to $15.00 million. For the next fiscal year, analysts expect that the business will report sales of $13.57 million, with estimates ranging from $5.00 million to $20.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that cover Solid Biosciences.
Solid Biosciences (NASDAQ:SLDB – Get Rating) last issued its earnings results on Wednesday, April 27th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.04). Solid Biosciences had a negative return on equity of 37.71% and a negative net margin of 660.25%. During the same period last year, the company posted ($0.19) EPS.
SLDB stock opened at $0.51 on Friday. The stock has a market cap of $57.53 million, a price-to-earnings ratio of -0.71 and a beta of 1.54. The company has a 50 day simple moving average of $0.98 and a 200 day simple moving average of $1.42. Solid Biosciences has a 1 year low of $0.50 and a 1 year high of $4.92.
In other news, COO Joel Solomon Zev Schneider sold 30,504 shares of the firm’s stock in a transaction dated Monday, March 14th. The stock was sold at an average price of $1.10, for a total transaction of $33,554.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 53,632 shares of company stock worth $59,004 over the last ninety days. Company insiders own 24.90% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in SLDB. Suvretta Capital Management LLC boosted its position in shares of Solid Biosciences by 5.2% during the 4th quarter. Suvretta Capital Management LLC now owns 6,287,193 shares of the company’s stock valued at $11,003,000 after purchasing an additional 313,000 shares in the last quarter. BlackRock Inc. lifted its stake in Solid Biosciences by 38.6% in the fourth quarter. BlackRock Inc. now owns 6,253,209 shares of the company’s stock valued at $10,942,000 after buying an additional 1,741,514 shares during the period. Artal Group S.A. boosted its holdings in shares of Solid Biosciences by 33.3% during the 3rd quarter. Artal Group S.A. now owns 3,000,000 shares of the company’s stock worth $7,170,000 after buying an additional 750,000 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Solid Biosciences by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 1,022,075 shares of the company’s stock valued at $1,788,000 after acquiring an additional 9,514 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its position in shares of Solid Biosciences by 51.3% during the 4th quarter. Renaissance Technologies LLC now owns 607,828 shares of the company’s stock valued at $1,064,000 after acquiring an additional 205,983 shares during the period. 66.95% of the stock is owned by institutional investors and hedge funds.
Solid Biosciences Company Profile (Get Rating)
Solid Biosciences Inc engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy.
- Get a free copy of the StockNews.com research report on Solid Biosciences (SLDB)
- Kellogg Company Flexes Pricing Power, Shares Move Higher
- Peak Growth Is Over For Etsy
- Uber Fails To Impress
- World Wresting Entertainment Stock is Hulking Up
- High-Yield Weyco Group Returns To Reasonable Levels
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.